Current treatment options and response rates in children with chronic hepatitis C

Figure 1 Distribution of genotypes in the five representative prospective trials using polyethylene glycol-interferon α-2b and polyethylene glycol-interferon α-2a in combination with ribavirin, published between 2005 and 2011.

Figure 2 Sustained viral response in five large prospective trials with polyethylene glycol-interferon α-2b¹/α-2a² and ribavirin stratified for genotype and viral load[27,28,30-32]. G: Genotype; HVL: High viral load, > 600  000 U/mL, (Wirth et al[32]), > 500  000 U/mL (Sokal et al[30]); LVL: Low viral load, < 600  000 U/mL (Wirth et al[32]), < 500  000 U/mL (Sokal et al[30]).